Study on the Association Between the Systemic Immune-Inflammation Index and Polycystic Ovary Syndrome in Women Undergoing in vitro Fertilization for Subfertility
Authors:
Open Access
- 1 July 2026
- journal article
- research article
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 18, 1-12
Abstract
Purpose: Polycystic ovary syndrome (PCOS) is closely associated with chronic low-grade inflammation. Systemic immune-inflammation index (SII) based on complete blood cell count has shown superior discriminative value in a variety of diseases, but its role in PCOS is still unclear. This study aimed to investigate the association between SII and PCOS in women undergoing their first in vitro fertilization (IVF) treatment with a gonadotropin-releasing hormone (GnRH) antagonist protocol. Materials and Methods: A total of 334 women undergoing their first IVF treatment with a GnRH antagonist protocol from January 2019 to December 2025 were included in this study. They were divided into the PCOS group (n=160) and the non-PCOS group (n=174). Demographic and physical indicators, reproductive endocrine indicators, systemic inflammatory indicators, infertility situation, ovulation induction treatment parameters, and trigger day indicators were collected. Binary logistic regression was used to identify the independent associated factors of PCOS. Results: The results of the multivariate analysis indicated that anti-Mullerian hormone (AMH) (OR=1.437, 95% CI: 1.222– 1.690, P< 0.001), basal follicle-stimulating hormone (FSH) (OR=0.718, 95% CI: 0.519– 0.993, P= 0.046), luteinising hormone (LH) (OR=1.293, 95% CI: 1.100– 1.519, P=0.002), testosterone (T) (OR=14.533, 95% CI: 2.162– 97.677, P=0.006), SII (OR=2.030, 95% CI: 1.079– 3.819, P=0.028), and LH level on the trigger day (OR=1.284, 95% CI: 1.061– 1.554, P=0.010) were independently associated with PCOS. Conclusion: Among patients undergoing their first IVF treatment, SII was independently associated with PCOS. This further supported the crucial role of chronic low-grade inflammation in the pathophysiology of PCOS. In the future, its efficacy needs to be verified through large-scale studies. Before it is fully confirmed, it is not recommended to use it as an independent clinical tool.Keywords
This publication has 48 references indexed in Scilit:
- Interplay between interleukin-6 signaling and the vascular endothelium in cytokine stormsExperimental & Molecular Medicine, 2021
- Systemic Immune-Inflammation Index (SII) Predicts Increased Severity in Psoriasis and Psoriatic Arthritis.2020
- Characteristics of polycystic ovary syndrome throughout lifeTherapeutic Advances in Reproductive Health, 2020
- Pathophysiologic mechanisms of obesity- and chronic inflammation-related genes in etiology of polycystic ovary syndrome2019
- Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current PerspectivesThe Application of Clinical Genetics, 2019
- The International Glossary on Infertility and Fertility Care, 2017Fertility and Sterility, 2017
- Gonadotrophin-releasing hormone antagonists for assisted reproductive technologyCochrane Database of Systematic Reviews, 2016
- A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expressionDARU Journal of Pharmaceutical Sciences, 2014
- GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysisReproductive BioMedicine Online, 2006
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)Human Reproduction, 2004